Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Abstract

Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.

1 .- 29 . (canceled) 
     
     
         30 . A compound having Formula 2 or Formula 3: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 R 1  is substituted naphthyl; 
 each R 4  is R 2 , OR a , C(═O)R a , C(═O)NR 2 R 3 , NR 2 R 3 , NR 2 R 3 , NR b (═O)R a , SR a , SOR a , SO 2 R a , SO 2 NHR a , SO 2 NR 2 R 3 , NCOR a , halogen, trihalomethyl, CN, S═O, or nitro; 
 each R a  can independently be H, optionally substituted hydrocarbyl, optionally substituted aryl, or optionally substituted heteroaryl; 
 R 2  and R 3  are each independently R a , C(═O)R a , or SO 2 R a , or R 2  and R 3  form an optionally substituted carbocyclic, heterocarbocyclic, aryl or heteroaryl ring; and 
 R 5  is H. 
 
     
     
         31 . The compound of  claim 30 , or a pharmaceutically acceptable salt thereof, wherein each R 4  is independently H or SO 2 NR 2 R 3  wherein R 2  and R 3  form an optionally substituted carbocyclic, heterocarbocyclic, aryl or heteroaryl ring. 
     
     
         32 . The compound of  claim 30 , or a pharmaceutically acceptable salt thereof, wherein each R 4  is independently H or SO 2 NR 2 R 3  wherein R 2  and R 3  form an optionally substituted heterocyclic ring selected from pyrrolidine, piperidine, morpholine, and piperazine. 
     
     
         33 . The a pharmaceutical composition comprising the compound of  claim 30 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         34 . A method of modulating the innate immune response in a eukaryotic cell, comprising administering to the cell a compound of  claim 30 , or a pharmaceutically acceptable salt thereof. 
     
     
         35 . The method of  claim 34  wherein the cell is in vivo. 
     
     
         36 . The method of  claim 34  wherein the cell is in vitro.